Blood test for tumor DNA to guide chemotherapy after colon cancer surgery
Tests blood tumor DNA to guide chemotherapy in colon cancer.
Plain-language title generated from the registry record
Registry title: Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial
Key facts
- Where
- 's-Hertogenbosch, Alkmaar, Almelo, Almere Stad, Amersfoort, Amsterdam, Arnhem, Breda, Delft, Deventer, Dordrecht, Ede, Goes, Gorinchem, Haarlem, Harderwijk, Maastricht, Middelharnis, Nieuwegein, Nijmegen, Roosendaal, Rotterdam, The Hague, Uden, Utrecht, Veldhoven, Venlo, and Weert, NetherlandsSee the 29 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage II colon cancer who had surgery and are not thought to need chemotherapy. Blood is tested for tumor DNA after surgery to decide on chemotherapy.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Stage II colon cancer, confirmed by tissue examination
- Earlier treatment
- Must have had no complete-resection failure: the tumor must have been fully removed. People with an indication for adjuvant chemotherapy cannot join.
Main reasons for not taking part
- The treating doctor sees a need for chemotherapy after surgery
- Another cancer in the past 5 years (treated carcinoma in situ or skin cancer other than melanoma is allowed)
- The tumor was not completely removed (R1 or R2 resection)
- Cannot take fluoropyrimidines or oxaliplatin
- Pregnancy
Read by machine on 9 November 2026.
Where in Netherlands
- Jeroen Bosch Ziekenhuis's-Hertogenbosch, NetherlandsTaking people
- Noordwest ZiekenhuisgroepAlkmaar, NetherlandsTaking people
- Ziekenhuisgroep TwenteAlmelo, NetherlandsTaking people
- FlevoziekenhuisAlmere Stad, NetherlandsTaking people
- Meander Medisch CentrumAmersfoort, NetherlandsTaking people
- NKI-AVLAmsterdam, NetherlandsTaking people
- RijnstateArnhem, NetherlandsTaking people
- Amphia ZiekenhuisBreda, NetherlandsTaking people
- Reinier de Graaf GasthuisDelft, NetherlandsTaking people
- Deventer ZiekenhuisDeventer, NetherlandsTaking people
- Albert Schweizer ZiekenhuisDordrecht, NetherlandsTaking people
- Ziekenhuis Gelderse ValleiEde, NetherlandsTaking people
- Admiraal de Ruyter ZiekenhuisGoes, NetherlandsTaking people
- RivasGorinchem, NetherlandsTaking people
- Spaarne GasthuisHaarlem, NetherlandsTaking people
- Ziekenhuis St JansdalHarderwijk, NetherlandsTaking people
- Maastricht UMCMaastricht, NetherlandsTaking people
- Van Weel-Bethesda ZiekenhuisMiddelharnis, NetherlandsTaking people
- St. Antonius ZiekenhuisNieuwegein, NetherlandsTaking people
- Canisius Wilhelmina ZiekenhuisNijmegen, NetherlandsTaking people
- Bravis ZiekenhuisRoosendaal, NetherlandsTaking people
- Ikazia ZiekenhuisRotterdam, NetherlandsTaking people
- Haaglanden MCThe Hague, NetherlandsTaking people
- BernhovenUden, NetherlandsTaking people
- DiakonessenhuisUtrecht, NetherlandsTaking people
- UMC UtrechtUtrecht, NetherlandsTaking people
- Maxima Medisch CentrumVeldhoven, NetherlandsTaking people
- VieCuri Medisch CentrumVenlo, NetherlandsTaking people
- St. Jans GasthuisWeert, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- UMC Utrecht
- Trial code
- NCT06434896
- Record updated
- 12 May 2026
- Original description
Patients in the Prospective Dutch ColoRectal Cancer cohort (PLCRC) with non-metastatic colon cancer that gave consent for additional blood withdrawals are enrolled in the observational PLCRC-MEDOCC substudy. In this study, blood is collected before surgery, after surgery and during follow-up. Within PLCRC-MEDOCC, patients with stage II colon cancer that are not considered to have an indication for adjuvant chemotherapy, can be included in the MEDOCC-CrEATE subcohort under the condition that they gave informed consent in PLCRC for biobanking of tissue and for future studies (Trial within Cohorts design).Read full original descriptionShow less
Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial
Patients in the Prospective Dutch ColoRectal Cancer cohort (PLCRC) with non-metastatic colon cancer that gave consent for additional blood withdrawals are enrolled in the observational PLCRC-MEDOCC substudy. In this study, blood is collected before surgery, after surgery and during follow-up. Within PLCRC-MEDOCC, patients with stage II colon cancer that are not considered to have an indication for adjuvant chemotherapy, can be included in the MEDOCC-CrEATE subcohort under the condition that they gave informed consent in PLCRC for biobanking of tissue and for future studies (Trial within Cohorts design).
Patients included in MEDOCC-CrEATE will be randomized 1:1 to the (A) ctDNA-based treatment group versus (B) the standard of care group. A total of 1320 patients will be randomized. Patients randomized to the ctDNA-based treatment group will have their post-surgery samples analysed directly after informed consent for MEDOCC-CrEATE. All patients with detectable ctDNA will be offered adjuvant chemotherapy (3 months CAPOX). Patients with undetectable ctDNA will receive routine follow-up at the surgical department. The aim of this Trial within Cohorts study is to investigate how many patients with detectable ctDNA after surgery start with adjuvant chemotherapy.
Inclusion: Age ≥ 18 years; Informed consent for PLCRC with specific consent for:; additional blood withdrawals; collection and use of tissue for scientific research; invitation for future (experimental) research within the cohort, including TwiCs studies; Inclusion in observational PLCRC -MEDOCC substudy; Histological confirmed stage II colon cancer; Fit enough to receive treatment with combination chemotherapy (fluoropyrimidine and oxaliplatin) according to the treating physician.
Exclusion: Indication for adjuvant chemotherapy according to treating physician; Another malignancy in previous 5 years, with the exception of treated carcinoma in situ or skin cancer other than melanoma; Incomplete primary tumor resection (R1 or R2 resection); Contra-indication for fluoropyrimidines or oxaliplatin; Pregnancy.